Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
189 studies found for:    regeneron
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Not yet recruiting Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Condition: Dermatitis, Atopic
Interventions: Drug: dupilumab;   Drug: placebo
2 Completed
Has Results
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Condition: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: Biological: VEGF Trap-Eye 2.0mg;   Drug: Sham
3 Completed A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain
Condition: Sciatica
Interventions: Drug: REGN475;   Drug: Placebo Injection
4 Recruiting Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Condition: Rheumatoid Arthritis
Interventions: Drug: Sarilumab;   Drug: Tocilizumab
5 Recruiting A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies
Conditions: Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Drug: REGN1979 multiple dose levels
6 Not yet recruiting Study of REGN910 in Patients With Diabetic Macular Edema (DME)
Condition: Diabetic Macular Edema
Interventions: Drug: REGN910;   Drug: placebo;   Drug: IVT aflibercept injection
7 Not yet recruiting Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
Condition: Homozygous Familial Hypercholesterolemia
Intervention: Drug: REGN1500
8 Not yet recruiting Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Condition: Dermatitis, Atopic
Interventions: Drug: dupilumab;   Drug: placebo
9 Recruiting Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Condition: Atopic Dermatitis
Interventions: Drug: dupilumab;   Drug: placebo
10 Recruiting Study to Assess the Safety and Tolerability of Single Doses of REGN1500
Condition: Healthy Volunteers
Interventions: Drug: REGN1500;   Drug: placebo
11 Recruiting An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193
Condition: Healthy Volunteers
Interventions: Drug: REGN1193;   Other: Placebo
12 Recruiting Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Condition: Atopic Dermatitis
Interventions: Drug: Dupilumab;   Drug: placebo
13 Recruiting Study of REGN1193 in Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: REGN1193;   Drug: Placebo
14 Recruiting Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500
Condition: Metabolic Disorders
Interventions: Drug: REGN1500;   Drug: placebo
15 Active, not recruiting The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
Condition: Central Serous Chorioretinopathy
Intervention: Drug: Intravitreal Aflibercept Injection
16 Completed VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Biological: ziv-aflibercept
17 Completed Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Condition: Cancer
Intervention: Biological: ziv-aflibercept
18 Completed Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Condition: Cancer
Intervention: Biological: ziv-aflibercept
19 Completed VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Biological: ziv-aflibercept
20 Recruiting Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea
Condition: Corneal Neovascularization
Interventions: Drug: Subconjunctival aflibercept;   Other: Placebo: Standard of care only

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years